Dr Damien Kee
Honorary (Fellow)
Department of Medical Biology (WEHI)
118 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
DOI: 10.1158/1078-0432.CCR-25-40092026
Journal article
10P Established prognostic scores predict screen failure but not clinical outcomes in phase I oncology trials
DOI: 10.1016/j.esmoop.2026.1077872026
Journal article
HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.
DOI: 10.1200/jco.2026.44.16_suppl.e206732026
Journal article
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
DOI: 10.1200/jco.2026.44.16_suppl.95692026
Journal article
Genomic Therapy Matching in Rare and Refractory Cancers
DOI: 10.1001/jamaoncol.2026.01272026
Journal article
Translating ctDNA into cutaneous melanoma care: An international expert survey
DOI: 10.1016/j.ejca.2026.1166762023
Research grants (ARC, NHMRC, MRFF)
Using Real World Data to Drive Cancer Care Research and Delivery
RECENT SCHOLARLY WORKS
2026
Journal article
Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers: A Nonrandomized Clinical Trial
DOI: 10.1001/jamaoncol.2025.47212026
Journal article
Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review
DOI: 10.1111/ceo.700022026
Journal article
An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
DOI: 10.1038/s41591-026-04518-z2026
Journal article
Established Prognostic Scores Predict Screen Failure But Not Post-Enrollment Outcomes in Phase 1 Oncology Trials: A Single Centre Retrospective Audit
DOI: 10.1111/ajco.70151